Phase 2 study
Testing the safety and tolerability of Alogobat, administered as once-daily oral tablet.
Alogabat is a GABA-modulator which aims to restore GABA functioning which would improve symptoms and potentially aid brain development.
Below is a preliminary list of inclusion criteria.
See the full list of eligibility criteria on the clinical trials website.
- Clinical diagnosis of deletion genotype of Angelman syndrome
- Between 5 and 17 years old
- Able to undergo blood draws, ECG and EEG assessments
Rush Medical Center
New York, NY
Columbia University Medical Center
Carolina Institute for Development Disabilities University of North Carolina/School of Medicine
Bedford Park, Australia, South Australia
Flinders Medical Centre Recruiting
Hopital la Timone Enfants; Service de Pediatrie et Neurologie Pediatrique
Groupe Hospitalier Necker Enfants Malades
Roma, Lazio, Italy
Ospedale Pediatrico Bambino Gesù; Dip. Neuroscienze e Neuroriabilitazione
Genova, Liguria, Italy
IRCCS Istituto G. Gaslini; UOC Neurologia Pediatrica e Malattie Muscolari
Sabadell, Barcelona, Spain
Corporacio Sanitaria Parc Tauli